Foresite Capital ALEC Position
Active7-Fund ConvergenceForesite Capital initiated a new position in Alector Inc. (ALEC) in Q4 2025, holding $6.1M worth of shares across 3,887,200 shares.
ALEC is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Alector Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
6.7%
6.5 days to cover
Frequently Asked Questions
Does Foresite Capital own ALEC?
Yes. As of Q4 2025, Foresite Capital holds 3,887,200 shares of Alector Inc. (ALEC) valued at $6.1M. This data comes from their SEC 13F filing.
How many hedge funds own ALEC?
7 specialist biotech hedge funds currently hold ALEC, including EcoR1 Capital, Deep Track Capital, RTW Investments and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Foresite Capital first buy ALEC?
Foresite Capital's position in ALEC was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Foresite Capital's ALEC position increasing or decreasing?
Foresite Capital initiated a new position in ALEC in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ALECCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Foresite CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →